NB-AMLODIPINE DIN 02556723
Health Canada record
| Active ingredient(s) | AMLODIPINE BESYLATE 10 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C08CA01 AMLODIPINE |
| Original market date | 26-Aug-2025 |
| Current status date | 26-Aug-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
NB Pharma Inc. — licence 3-002798, currently licensed, last inspection rating C (2025-12-05).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AMLODIPINE BESYLATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02497492 | AMODIP FLAVOURED TABLETS | CEVA ANIMAL HEALTH INC | Tablet | AMLODIPINE BESYLATE 1.73 MG | Marketed |
| 02556707 | NB-AMLODIPINE | NB PHARMA INC. | Tablet | AMLODIPINE BESYLATE 2.5 MG | Marketed |
| 02556715 | NB-AMLODIPINE | NB PHARMA INC. | Tablet | AMLODIPINE BESYLATE 5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 35114 | 2025-04-02 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for AMLODIPINE BESYLATE
20 active FDA Drug Master Files.
Request a quote for NB-AMLODIPINE